This drug is seen as a potential therapeutic option for s-IBM patients.Amato et al. hypothesized that signaling of transforming growth factor β superfamily through ActRII, is implicated in the pathophysiology of s-IBM. The gene discussed is ACVR2A; the disease is inclusion body myositis.